The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages 330-333

  Rizzo, Manfredi ^a   Rini, Giovam Battista ^a   Spinas, Giatgen A ^b   Berneis, Kaspar ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cardiovascular risk; Cholesterol; Ezetimibe; LDL size; Small, dense LDL

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 67349093082     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.10.005     Document Type: Review

References (41)

1. Capps N. Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice. Int J Clin Pract 60 (2006) 867-869
2. Mikhailidis D.P., Wierzbicki A.S., Daskalopoulou S.S., et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 21 (2005) 959-969
3. Sweeney M.E., and Johnson R.R. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 3 (2007) 441-450
4. Florentin M., Liberopoulos E.N., and Elisaf M.S. Ezetimibe-associated adverse effects: what the clinician needs to know?. Int J Clin Pract 62 (2008) 88-96
5. Toth P.P., and Davidson M.H. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6 (2005) 131-139
6. Neal R.C., and Jones P.H. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manage 2 (2006) 31-38
7. McKenney J.M., Farnier M., Lo K.W., et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47 (2006) 1584-1587
8. Davidson M.H. Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?. Nat Clin Pract Cardiovasc Med 3 (2006) 594-595
9. Jelesoff N.E., Ballantyne C.M., Xydakis A.M., et al. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract 12 (2006) 159-164
10. Wierzbicki A.S., Doherty E., Lumb P.J., Chik G., and Crook M.A. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 21 (2005) 333-338
11. Mikhailidis D.P., Sibbring G.C., Ballantyne C.M., Davies G.M., and Catapano A.L. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 23 (2007) 2009-2026
12. Denke M., Pearson T., McBride P., et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes Vasc Dis Res 3 (2006) 93-102
13. Hildemann S.K., Barho C., Karmann B., et al. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 23 (2007) 713-719
14. Blagden M.D., and Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 23 (2007) 767-775
15. Kastelein J.J., Akdim F., Stroes E.S., et al., ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
16. Rizzo M., and Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM - Int J Med 99 (2006) 1-14
17. Krauss R., and Burke D. Identification of multiple subclasses of plasma low denstity lipoproteins in normal humans. J Lipid Res 23 (1982) 97-104
18. Packard C.J., and Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17 (1997) 3542-3556
19. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421. 23.
20. St Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the longterm risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25 (2005) 553-559
21. Kalogirou M., Tsimihodimos V., Gazi I., et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 23 (2007) 1169-1176
22. Geiss H.C., Otto C., and Parhofer K.G. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism 55 (2006) 599-604
23. Ose L., Reyes R., Johnson-Levonas A.O., et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 29 (2007) 2419-2432
24. Farnier M., Freeman M.W., Macdonell G., et al., The Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 26 (2005) 897-905
25. Tribble D.L., Farnier M., Macdonell G., et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 57 (2008) 796-801
26. Nakou E.S., Filippatos T.D., Georgoula M., et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 24 (2008) 1919-1929
27. Kalogirou M., Tsimihodimos V., Saougos V., et al. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pre-treatment. Arch Med Sci 3 (2007) 344-350
28. Hoefner D.M., Hodel S.D., O'Brien J.F., et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47 (2001) 266-274
29. Ensign W., Hill N., and Heward C.B. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 52 (2006) 1722-1727
30. Sacks F.M., and Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocr Metab 88 (2003) 4525-4532
31. Lamarche B., Lemieux I., and Despres J.P. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25 (1999) 199-211
32. Lada A.T., and Rudel L.L. Associations of low density lipoprotein particle composition with atherogenicity. Curr Opin Lipidol 15 (2004) 19-24
33. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387
34. Rizzo M., and Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 23 (2007) 1103-1111
35. Gazi I.F., Tsimihodimos V., Tselepis A.D., Elisaf M., and Mikhailidis D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 7 (2007) 53-72
36. Rizzo M., and Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther 20 (2006) 205-217
37. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 49 (2007) 2003-2009
38. Bays H.E., Neff D., Tomassini J.E., and Tershakovec A.M. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 6 4 (April 2008) 447-470
39. The SEAS Study. www.theheart.org, July 21, 2008.
40. Wierzbicki A.S. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract 62 (2008) 981-987
41. Griffin B.A., Caslake M.J., Yip B., et al. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83 (1990) 59-67